+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Vaccine Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 370 Pages
  • August 2023
  • Region: Global
  • Renub Research
  • ID: 5576812

Global Vaccine Market size is anticipated to reach US$ 92.32 Billion by 2028, according to the report. There has been substantial progress in the availability of critical public health vaccinations during the previous two decades. New vaccinations have been developed and distributed globally, saving many lives and preventing illness. However, a thorough examination of the global vaccination business indicates significant impediments that continue to exist. Biological preparations known as vaccine give recipients active acquired immunity to infectious illnesses. They encourage the immune system to generate antibodies that will defend against upcoming infections. Vaccine prevent diseases like MMR, control contagion, eradicate smallpox, and save lives.

The use of vaccinations in the treatment and prevention of infectious illnesses has many benefits. Immunization prevents disease spread, protecting vaccinated and unvaccinated individuals. Studies confirm vaccine' reliability, safety, and efficacy. Immunization costs less than treating preventable diseases, making it a cost-effective public health strategy.

Global vaccine market is projected to grow at a CAGR of 8.64% between 2022 and 2028

Vaccine remain the most effective method for preventing prevalent infectious diseases worldwide. In the United States, the incidence of influenza fluctuates annually, with approximately 38 million cases, 480,000 hospitalizations, and 34,000 deaths reported in 2022. Normally, 10% to 15% of the population is affected by the flu, but more severe seasons can lead to higher infection rates.

Vaccine technology has evolved, driven by the need for faster response and improved efficacy. Genetic engineering has enabled the development of new vaccine, including attenuated virus vaccine. Rapid detection and high concentration levels are achieved through advanced technologies. Innovation focuses on challenging targets, enhanced delivery systems, synthetic candidates, genomic analysis, antigen design, and nanoparticle delivery. These advancements revolutionize vaccine development for quicker deployment and increased effectiveness. However, vaccine development is a lengthy, complex, and expensive process lasting 10-15 years, influenced by variations in materials, equipment, and regulatory requirements, restricting market growth. As a result, the value of the global vaccine market was US$ 56.16 Billion in 2022.

Pneumococcal vaccine has a high share in the global vaccine market due to disease prevalence and emerging market demand

Vaccine market share shows that influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella segments make up the majority of the global vaccine market.

Pneumococcal illness is a deadly global hazard caused by Streptococcus pneumonia but can be prevented with vaccinations. Particularly pneumococcal conjugate vaccination (PCV13) for young children, they are commonly used. In areas with limited vaccine access, the demand for pneumococcal vaccine is rising. Their significant market share is driven by new discoveries, growing awareness, and improved accessibility.

United States is expected to continue to dominate the global vaccination industry in the years to come

By country, the global vaccine market is divided into the United States, Canada, Mexico, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World. The United States, with its robust pharmaceutical industry and leading vaccine manufacturers, including Pfizer, Merck, and Johnson & Johnson, holds a dominant position in the global vaccine market. 

The country strong regulatory framework ensures the safety and efficacy of vaccine, fostering public trust and high coverage rates. The large and diverse population creates a substantial demand for vaccine, while supportive government policies provide financial backing for research, development, procurement, and distribution. The United States leads the world vaccination industry due to early investments in vaccine research, a strong public health system, and a supportive regulatory framework.

Influenza vaccine lead to vaccinated people share in the global vaccine market

Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella are among the vaccine that make up the majority of the world vaccine market by number of persons who have received them. Influenza is a deadly respiratory infection, but vaccine reduce illness risk by 40% to 60% globally, including in the US. Emerging markets exhibit a growing demand for influenza vaccine due to high prevalence and limited access to vaccine. These factors contribute to the expected high market share of influenza vaccine in the global vaccine market. The seasonal nature of influenza also aids in vaccination planning, government mandates increase vaccination rates, and increasing public awareness of the importance of influenza vaccination drives demand for these vaccine.

Combo vaccine, which combine multiple vaccine into a single shot. Combo vaccine offer the convenience of a single shot for patients and healthcare providers while providing effective protection against a wider range of pathogens. They are generally safe, with risks of side effects similar to separate vaccine. Combo vaccine can save on administration costs and the need for multiple doses, making them more cost-effective. The growth of combo vaccine is supported by government initiatives, rising awareness of vaccination benefits, and advancements in vaccine technology, leading to improved and more accessible options for protecting against multiple diseases.

Pediatric vaccine grow in the global vaccine market due to childhood diseases and their prevention effectiveness

Adult and Pediatric are the types constituting the global vaccine market. Pediatric vaccinations, including MMR, prevent serious illnesses and save lives. With recommendations from health agencies like the CDC in the US, these vaccine are extensively used throughout the world. In emerging areas where there is limited access to vaccine yet a high prevalence of children's diseases, there is an increasing demand for pediatric vaccine. New pediatric vaccine, growing vaccination awareness, and improved global immunization access contribute to higher childhood immunization rates, driving the market share of pediatric vaccine.

Global vaccine market is anticipated to continue to be dominated by Pediatric Vaccine

Adult and pediatric are the two categories in the global vaccine market. Worldwide, pediatric vaccine are crucial in preventing prevalent childhood diseases. For instance, measles, mumps, and rubella (MMR) can have severe consequences. Pediatric vaccine have high efficacy rates, such as the 97% effectiveness of the MMR vaccine. They are widely used, and experience growing demand, particularly in emerging markets with limited vaccine access. The development of new vaccine broadens protection against childhood diseases. Increasing awareness of vaccination importance and improved vaccine accessibility contribute to their global vaccine market features and trends growth. Governments often mandate pediatric vaccine due to the higher transmission risk and impact on children's health, further emphasizing their importance.

Key Players

GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited are some of the top companies competing in the global vaccine market. Market demand, R&D, patent protection, pricing, regulatory approvals, manufacturing capabilities, and global expansion drive competition among vaccine companies to meet needs, innovate, gain exclusivity, attract customers, ensure quality, and expand market reach.

In January 2022 - In order to assess the safety, immunogenicity, and tolerability of a potential Omicron-based vaccination in adults between the ages of 18 and 55, Pfizer Inc. and BioNTech SE started a clinical trial.

This report “Global Vaccine Market, Vaccine Market Share (Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella), Country (United States, Canada, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Mexico, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World), Vaccinated People (Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella), Categories (Adult, and pediatric), Companies (GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited)” provides a detailed analysis of Global Vaccine Market.

Vaccine Market Share - Global Vaccine Market has been covered from 14 viewpoints:

1. Influenza
2. HPV
3. Zoster
4. MMR
5 Pneumococcal
6. Meningococcal
7. Hepatitis
8. DTap/Tdap
9. Travel & Miscellaneous
10. HIB
11. Combos
12. Polio
13. Rotavirus
14. Varicella

Country - Global Vaccine Market has been covered from 21 viewpoints:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 United Kingdom
2.2 Germany
2.3 France
2.4 Russia
2.5 Italy
2.6 Spain
2.7 Switzerland

3. Asia Pacific

3.1 India
3.2 China
3.3 Japan
3.4 Australia
3.5 South Korea

4. Latin America

4.1 Mexico
4.2 Brazil
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

6. Rest of the World

Vaccinated People - Global Vaccine Market has been covered from 13 viewpoints:

1. Influenza
2. Cervical Cancer
3. Zoster
4. MMR
5. Pneumococcal
6. Meningococcal
7. Hepatitis
8. DTap/Tdap
9. HIB
10. Combos
11. Polio
12. Rotavirus
13. Varicella

Category - Global Vaccine Market has been covered from 2 viewpoints:

1. Adult
2. Pediatric

Company Insights:

  • Oveview
  • Recent Development and Initiatives
  • Sales Analysis

Company Analysis:

1. GlaxoSmithKline plc,
2. AstraZeneca plc, 
3. Sanofi Pasteur, 
4. Pfizer Inc.,
5. CSL Limited

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Driver
4.2 Challenges
5. Global Vaccines Market
5.1 Adult Vaccines Market
5.2 Pediatric (Infant) Vaccines Market
6. Global Vaccinated People
6.1 Adult Vaccinated People
6.2 Pediatric (Infant) Vaccinated People
7. Share Analysis - Global Vaccines Market & People
7.1 Vaccine Market Share
7.2 By Country
7.3 Vaccinated People Share
8. Categories - Global Vaccines Market & People Share
8.1 Adult VsPediatric (Infant) Vaccines Market Share
8.2 Adult VsPediatric (Infant) Vaccines Number Share
9. Disease wise - Vaccines Market and Forecast
9.1 Influenza - Total Vaccines Market
9.1.1 Influenza - Adult Vaccines Market
9.1.2 Influenza - Pediatric (Infant) Vaccines Market
9.2 Cervical Cancer (HPV) - Vaccines Market
9.3 Zoster (Shingles) - Vaccines Market
9.4 MMR (Measles, Mumps, and Rubella Vaccine) - Total Vaccines Market
9.4.1 MMR - Adult Vaccines Market
9.4.2 MMR - Pediatric (Infant) Vaccines Market
9.5 Pneumococcal - Total Vaccines Market
9.5.1 Pneumococcal - Adult Vaccines Market
9.5.2 Pneumococcal - Pediatric (Infant) Vaccines Market
9.6 Meningococcal - Total Vaccines Market
9.6.1 Meningococcal - Adult Vaccines Market
9.6.2 Meningococcal - Pediatric (Infant) Vaccines Market
9.7 Hepatitis - Total Vaccines Market
9.7.1 Hepatitis - Adult Vaccines Market
9.7.2 Hepatitis - Pediatric (Infant) Vaccines Market
9.8 TdaP and DTaP - Total Vaccines Market
9.8.1 TdaP - Adult Vaccines Market
9.8.2 DTaP - Pediatric (Infant) Vaccines Market
9.9 Travel and Miscellaneous - Vaccines Market
9.10 HaemophilusInfluenzae Type B (HIB) - Vaccines Market
9.11 Combos (Combination) - Vaccines Market
9.12 Polio - Vaccines Market
9.13 Rotavirus - Vaccines Market
9.14 Varicella - Vaccines Market
9.14.1 Varicella - Adult Vaccines Market
9.14.2 Varicella - Pediatric (Infant) Vaccines Market
10. Disease wise - Numbers of Vaccinated People & Forecast
10.1 Influenza - Total Number of Vaccinated People
10.1.1 Influenza - Number of Vaccinated Adults
10.1.2 Influenza - Number of Vaccinated Infants
10.2 Cervical Cancer (HPV) - Number of Vaccinated People
10.3 Zoster (Shingles) - Number of Vaccinated People
10.4 MMR - Total Number of Vaccinated People
10.4.1 MMR - Number of Vaccinated Adults
10.4.2 MMR - Number of Vaccinated Infants (Pediatric)
10.5 Pneumococcal - Total Number of Vaccinated People
10.5.1 Pneumococcal - Number of Vaccinated Adults
10.5.2 Pneumococcal - Number of Vaccinated Infants
10.6 Meningococcal - Total Number of Vaccinated People
10.6.1 Meningococcal - Number of Vaccinated Adults
10.6.2 Meningococcal - Number of Vaccinated Infants
10.7 Hepatitis - Total Number of Vaccinated People
10.7.1 Hepatitis - Number of Vaccinated Adults
10.7.2 Hepatitis - Number of Vaccinated Infants
10.8 TdaP and DTaP - Total Number of Vaccinated People
10.8.1 TdaP - Number of Vaccinated Adults
10.8.2 DTaP - Number of Vaccinated Infants
10.9 Hib (HaemophilusInfluenzae Type B) - Number of Vaaccinated Infants
10.10 Combos (Combination Vaccines) - Number of Vaccinated Infants
10.11 Polio - Number of Infants Immunized and Forecast
10.12 Rotavirus - Number of Vaccinated Infants
10.13 Varicella - Total Number of Vaccinated People
10.13.1 Varicella - Number of Vaccinated Adults
10.13.2 Varicella - Number of Vaccinated Infants
11. Country - Global Vaccine Market
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Russia
11.2.5 Italy
11.2.6 Spain
11.2.7 Switzerland
11.3 Asia Pacific
11.3.1 India
11.3.2 China
11.3.3 Japan
11.3.4 Australia
11.3.5 South Korea
11.4 Latin America
11.4.1 Mexico
11.4.2 Brazil
11.4.3 Argentina
11.5 Middle East & Africa
11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa
11.6 Rest of the World
12. Porter’s Five Forces
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strengths
13.2 Weaknesses
13.3 Opportunities
13.4 Threats
14. Vaccines Key Players Sales
14.1 GlaxoSmithKline plc.
14.1.1 Overview
14.1.2 Recent Development
14.1.3 Financial Insights
14.2 Astrazeneca plc
14.2.1 Overview
14.2.2 Recent Development
14.2.3 Financial Insights
14.3 Sanofi Pasteur
14.3.1 Overview
14.3.2 Recent Development
14.3.3 Financial Insights
14.4 Pfizer, Inc.
14.4.1 Overview
14.4.2 Recent Development
14.4.3 Financial Insights
14.5 CSL Limited sales
14.5.1 Overview
14.5.2 Recent Development
14.5.3 Financial Insights
List of Figures
Figure 01: Global - Vaccines Market (Million US$), 2018 - 2022
Figure 02: Global - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 03: Global - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 04: Global - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 05: Global - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 06: Global - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 07: Global - Vaccinated People Volume (Million), 2018 - 2022
Figure 08: Global - Forecast for Vaccinated People Volume (Million), 2023 - 2028
Figure 09: Global - Adult Vaccinated People Volume (Million), 2018 - 2022
Figure 10: Global - Forecast for Adult Vaccinated People Volume (Million), 2023 - 2028
Figure 11: Global - Pediatric (Infant) Vaccinated People Volume (Million), 2018 - 2022
Figure 12: Global - Forecast for Pediatric (Infant) Vaccinated People Volume (Million), 2023 - 2028
Figure 13: Influenza - Total Vaccines Market (Million US$), 2018 - 2022
Figure 14: Influenza - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 15: Influenza - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 16: Influenza - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 17: Influenza - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 18: Influenza - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 19: Cervical Cancer (HPV) - Vaccines Market (Million US$), 2018 - 2022
Figure 20: Cervical Cancer (HPV) - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 21: Zoster (Shingles) - Vaccines Market (Million US$), 2018 - 2022
Figure 22: Zoster (Shingles) - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 23: MMR - Total Vaccines Market (Million US$), 2018 - 2022
Figure 24: MMR - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 25: MMR - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 26: MMR - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 27: MMR - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 28: MMR - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 29: Pneumococcal - Total Vaccines Market (Million US$), 2018 - 2022
Figure 30: Pneumococcal - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 31: Pneumococcal - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 32: Pneumococcal - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 33: Pneumococcal - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 34: Pneumococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 35: Meningococcal - Total Vaccines Market (Million US$), 2018 - 2022
Figure 36: Meningococcal - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 37: Meningococcal - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 38: Meningococcal - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 39: Meningococcal - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 40: Meningococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 41: Hepatitis - Total Vaccines Market (Million US$), 2018 - 2022
Figure 42: Hepatitis - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 43: Hepatitis - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 44: Hepatitis - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 45: Hepatitis - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 46: Hepatitis - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 47: TdaP and DTaP - Total Vaccines Market (Million US$), 2018 - 2022
Figure 48: TdaP and DTaP - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
Figure 49: TdaP - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 50: TdaP - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 51: DTaP - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 52: DTaP - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 53: Travel and Miscellaneous - Vaccines Market (Million US$), 2018 - 2022
Figure 54: Travel and Miscellaneous - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 55: Haemophilus Influenzae Type B (HIB) - Vaccines Market (Million US$), 2018 - 2022
Figure 56: Haemophilus Influenzae Type B (HIB) - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 57: Combos (Combination) - Vaccines Market (Million US$), 2018 - 2022
Figure 58: Combos (Combination) - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 59: Polio - Vaccines Market (Million US$), 2018 - 2022
Figure 60: Polio - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 61: Rotavirus - Vaccines Market (Million US$), 2018 - 2022
Figure 62: Rotavirus - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 63: Varicella - Vaccines Market (Million US$), 2018 - 2022
Figure 64: Varicella - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 65: Varicella - Adult Vaccines Market (Million US$), 2018 - 2022
Figure 66: Varicella - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
Figure 67: Varicella - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
Figure 68: Varicella - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
Figure 69: Influenza - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 70: Influenza - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 71: Influenza - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 72: Influenza - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 73: Influenza - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 74: Influenza - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 75: Cervical Cancer (HPV) - Number of Vaccinated People (Million), 2018 - 2022
Figure 76: Cervical Cancer (HPV) - Forecast for Number of Vaccinated People (Million), 2023 - 2028
Figure 77: Zoster (Shingles) - Number of Vaccinated People (Million), 2018 - 2022
Figure 78: Zoster (Shingles) - Forecast for Number of Vaccinated People (Million), 2023 - 2028
Figure 79: MMR - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 80: MMR - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 81: MMR - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 82: MMR - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 83: MMR - Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2022
Figure 84: MMR - Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2023 - 2028
Figure 85: Pneumococcal - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 86: Pneumococcal - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 87: Pneumococcal - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 88: Pneumococcal - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 89: Pneumococcal - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 90: Pneumococcal - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 91: Meningococcal - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 92: Meningococcal - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 93: Meningococcal - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 94: Meningococcal - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 95: Meningococcal - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 96: Meningococcal - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 97: Hepatitis - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 98: Hepatitis - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 99: Hepatitis - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 100: Hepatitis - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 101: Hepatitis - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 102: Hepatitis - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 103: TdaP and DTaP - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 104: TdaP and DTaP - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 105: TdaP - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 106: TdaP - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 107: DTaP - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 108: DTaP - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 109: Hib (Haemophilus Influenzae Type B) - Number of Vaaccinated Infants (Million), 2018 - 2022
Figure 110: Hib (Haemophilus Influenzae Type B) - Forecast for Number of Vaaccinated Infants (Million), 2023 - 2028
Figure 111: Combos (Combination Vaccines) - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 112: Combos (Combination Vaccines) - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 113: Polio - Number of Infants Immunized and Forecast (Million), 2018 - 2022
Figure 114: Polio - Forecast for Number of Infants Immunized and Forecast (Million), 2023 - 2028
Figure 115: Rotavirus - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 116: Rotavirus - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 117: Varicella - Total Number of Vaccinated People (Million), 2018 - 2022
Figure 118: Varicella - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
Figure 119: Varicella - Number of Vaccinated Adults (Million), 2018 - 2022
Figure 120: Varicella - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
Figure 121: Varicella - Number of Vaccinated Infants (Million), 2018 - 2022
Figure 122: Varicella - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
Figure 123: United States - Vaccines Market (Million US$), 2018 - 2022
Figure 124: United States - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 125: Canada - Vaccines Market (Million US$), 2018 - 2022
Figure 126: Canada - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 127: United Kingdom - Vaccines Market (Million US$), 2018 - 2022
Figure 128: United Kingdom - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 129: Germany - Vaccines Market (Million US$), 2018 - 2022
Figure 130: Germany - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 131: France - Vaccines Market (Million US$), 2018 - 2022
Figure 132: France - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 133: Russia - Vaccines Market (Million US$), 2018 - 2022
Figure 134: Russia - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 135: Italy - Vaccines Market (Million US$), 2018 - 2022
Figure 136: Italy - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 137: Spain - Vaccines Market (Million US$), 2018 - 2022
Figure 138: Spain - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 139: Switzerland - Vaccines Market (Million US$), 2018 - 2022
Figure 140: Switzerland - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 141: India - Vaccines Market (Million US$), 2018 - 2022
Figure 142: India - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 143: China - Vaccines Market (Million US$), 2018 - 2022
Figure 144: China - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 145: Japan - Vaccines Market (Million US$), 2018 - 2022
Figure 146: Japan - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 147: Australia - Vaccines Market (Million US$), 2018 - 2022
Figure 148: Australia - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 149: South Korea - Vaccines Market (Million US$), 2018 - 2022
Figure 150: South Korea - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 151: Mexico - Vaccines Market (Million US$), 2018 - 2022
Figure 152: Mexico - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 153: Brazil - Vaccines Market (Million US$), 2018 - 2022
Figure 154: Brazil - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 155: Argentina - Vaccines Market (Million US$), 2018 - 2022
Figure 156: Argentina - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 157: Saudi Arabia - Vaccines Market (Million US$), 2018 - 2022
Figure 158: Saudi Arabia - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 159: UAE - Vaccines Market (Million US$), 2018 - 2022
Figure 160: UAE - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 161: South Africa - Vaccines Market (Million US$), 2018 - 2022
Figure 162: South Africa - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 163: Rest of the World - Vaccines Market (Million US$), 2018 - 2022
Figure 164: Rest of the World - Forecast for Vaccines Market (Million US$), 2023 - 2028
Figure 165: GlaxoSmithKline, plc. - Global Revenue (Billion US$), 2018 - 2022
Figure 166: GlaxoSmithKline, plc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 167: Astrazeneca plc - Global Revenue (Million US$), 2018 - 2022
Figure 168: Astrazeneca plc - Forecast for Global Revenue (Million US$), 2023 - 2028
Figure 169: Sanofi Pasteur - Global Revenue (Billion US$), 2018 - 2022
Figure 170: Sanofi Pasteur - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 171: Pfizer, Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 172: Pfizer, Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 173: CSL Limited - Global Revenue (Billion US$), 2018 - 2022
Figure 174: CSL Limited - Forecast for Global Revenue (Billion US$), 2023 - 2028
List of Tables
Table 01: Global - Vaccines Market Share (Percent), 2018 - 2022
Table 02: Global - Forecast for Vaccines Market Share (Percent), 2023 - 2028
Table 03: Global - Vaccines Market Share by Country (Percent), 2018 - 2022
Table 04: Global - Forecast for Vaccines Market Share by Country (Percent), 2023 - 2028
Table 05: Global - Vaccinated People Share (Percent), 2018 - 2022
Table 06: Global - Forecast for Vaccinated People Share (Percent), 2023 - 2028
Table 07: Global - Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2022
Table 08: Global - Forecast for Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2023 - 2028
Table 09: Global - Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2018 - 2022
Table 10: Global - Forecast for Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2023 - 2028

Companies Mentioned

  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Sanofi Pasteur
  • Pfizer Inc.
  • CSL Limited

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information